Wegovy (semaglutide 2.4mg) is a GLP-1 receptor agonist FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. It is administered as a once-weekly injection at doses from 0.25mg up to 2.4mg. Semaglutide works by mimicking the GLP-1 hormone, reducing appetite, slowing gastric emptying, and improving satiety signaling in the brain. Weight Method's compounded semaglutide is a separate, individualized treatment overseen by your provider; individual results vary and no specific outcome can be promised.
Weight Method offers compounded semaglutide and tirzepatide programs from $199/month with virtual consultations and licensed providers who monitor your progress.
Key Fact
Semaglutide reduces appetite and slows gastric emptying. With Weight Method, your provider reviews your health profile, builds an individualized plan, and adjusts dosing based on how you respond over time. Outcomes differ widely from person to person.
Source: Provider-monitored, individualized treatment
Semaglutide 2.4mg is a GLP-1 receptor agonist that reduces appetite. Weight Method's compounded semaglutide is provider-monitored and individualized — results vary by person.
Semaglutide is a GLP-1 receptor agonist that reduces appetite and caloric intake. There is no typical result — what you experience depends on your starting weight, adherence to lifestyle changes, and individual metabolic factors, and no specific amount of weight loss can be promised. Weight Method provides compounded semaglutide with full clinical oversight at $154/mo; your provider monitors your progress and adjusts your plan throughout treatment.
Most patients notice reduced appetite within 1-2 weeks, visible weight loss by months 2-3, and maximum results after 12-16 months at the 2.4mg maintenance dose.
Appetite suppression and reduced food noise typically begin within 1-2 weeks of the first Wegovy injection, even at the starting 0.25mg dose. Noticeable weight loss — enough for others to observe — generally occurs by months 2-3 as dosing escalates toward the maintenance level of 2.4mg. The most rapid period of weight loss is typically between months 3-9, with results continuing to accumulate through 12-16 months. Weight loss tends to plateau around 15-17 months as the body stabilizes at a new set point. Your Weight Method provider tracks your trajectory at each stage and adjusts your plan accordingly.
Expect gradual dose increases over 16-20 weeks, mild GI side effects initially, individualized progress that varies by person, and regular provider check-ins.
Individual results vary widely, and no specific amount of weight loss can be promised. Semaglutide tends to work best when combined with a reduced-calorie diet and increased physical activity. Plateaus are a normal part of the process, typically occurring around months 6-8 before weight loss resumes. Weight Method's clinical team provides regular check-ins to adjust your treatment plan and maintain momentum. Your provider is the right source for what you can realistically expect in your situation.
Patients with BMI 30 or higher, those who have not used GLP-1 medications before, and individuals who combine medication with lifestyle changes see the strongest results.
Patients with higher starting BMIs tend to lose a greater absolute amount of weight, though responses differ from person to person. Strong early appetite reduction in weeks 1-4 can be an encouraging sign. Individuals who engage in regular physical activity and make dietary adjustments alongside the medication generally do better than those relying on the drug alone. Patients with prediabetes or insulin resistance sometimes see different response patterns. Your Weight Method provider uses your early response to tailor dosing and lifestyle recommendations.
Take our 2-minute quiz to see if you qualify for GLP-1 treatment.
Start QuizFree consultation. No commitment.